{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:23Z","timestamp":1740144203102,"version":"3.37.3"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"crossref","award":["2018ZX10302104"],"award-info":[{"award-number":["2018ZX10302104"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Asymptomatic cryptococcal antigenemia is a state of cryptococcal infection commonly seen in immunocompromised HIV-infected persons. Without early intervention, a proportion of HIV-infected persons with cryptococcal antigenemia may go on to develop cryptococcosis, especially cryptococcal meningitis, which is associated with high mortality. The benefits of antifungal intervention and optimal therapeutic intervention regimens for HIV-infected persons with cryptococcal antigenemia remain controversial. We therefore designed the present study in order to investigate the necessity of, and the optimal regimens for antifungal intervention in the clinical management of cryptococcal antigenemia in HIV-infected populations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/Design:<\/jats:title>\n            <jats:p>This study will be an open-labeled, multi-center, prospective, randomized controlled trial, and 450 eligible participants will be randomized into a control arm and 2 intervention arms at a 1:1:1 ratio, with 150 subjects in each arm. Participants in the control arm will not receive antifungal treatment during the study period. Participants in intervention arm 1 will receive oral fluconazole 800\u200amg\/day for 2 weeks, followed by 400\u200amg\/day for 8 weeks and 200\u200amg\/day for 42 weeks, and participants in intervention arm 2 will receive oral fluconazole 400\u200amg\/day for 52 weeks. The primary outcome is the incidence of CM among the 3 groups during the study period. The secondary outcomes include the differences in all-cause mortality, proportion of patients reverting to blood CrAg negativity, change of CrAg titers, and adverse events among the 3 groups during the follow-up period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>We envisage that the results of this study will reveal the necessity of, and the optimal therapeutic regimens for, antifungal intervention in clinical management of HIV-infected patients with cryptococcal antigenemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>The study was registered as one of the 12 clinical trials under a general project at the Chinese Clinical Trial Registry on February 1, 2019, and the registration number of the general project is ChiCTR1900021195.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000022874","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T19:07:53Z","timestamp":1603912073000},"page":"e22874","source":"Crossref","is-referenced-by-count":1,"title":["A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections"],"prefix":"10.1097","volume":"99","author":[{"given":"Feng","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Qiu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis","volume":"17","author":"Rajasingham","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R2-20230916","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","author":"Park","year":"2009","journal-title":"AIDS"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/655143","article-title":"Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count &lt; or = 100\u200acells\/microL who start HIV therapy in resource-limited settings","volume":"51","author":"Meya","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/QAI.0000000000001894","article-title":"Reflexive laboratory-based cryptococcal antigen screening and preemptive fluconazole therapy for cryptococcal antigenemia in HIV-infected individuals with Cd4 &lt;100\u200acells\/microl: a stepped-wedge, cluster-randomized trial","volume":"80","author":"Meya","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-20230916","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"R8-20230916","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1097\/QAI.0b013e31824c837e","article-title":"Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care","volume":"59","author":"Rajasingham","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R9-20230916","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/QAI.0000000000001669","article-title":"A Prospective evaluation of a multisite cryptococcal screening and treatment program in HIV Clinics in Uganda","volume":"78","author":"Nalintya","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R11-20230916","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(15)60164-7","article-title":"Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial","volume":"385","author":"Mfinanga","year":"2015","journal-title":"Lancet"},{"key":"R12-20230916","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/cid\/ciz453","article-title":"Cryptococcal meningitis screening and community-based early adherence support in people with advanced human immunodeficiency virus infection starting antiretroviral therapy in tanzania and zambia: a cost-effectiveness analysis","volume":"70","author":"Kimaro","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T02:02:54Z","timestamp":1694829774000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022874"}},"subtitle":["Study protocol for the optimal early intervention for cryptococcal antigenemia in HIV-infected patients"],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":10,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022874","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,10,30]]}}}